Can a heart drug fix tiny vessel damage in metabolic syndrome?

NCT ID NCT05711719

First seen Jan 04, 2026 · Last updated Apr 28, 2026 · Updated 21 times

Summary

This study tested whether vericiguat, a drug that helps blood vessels relax, could improve heart artery function in 45 adults with metabolic syndrome (a cluster of conditions like high blood pressure, large waist, and abnormal cholesterol). Participants took either vericiguat or a placebo for six weeks, and researchers used MRI scans to measure changes in artery size during exercise. The goal was to see if the drug could reverse early blood vessel damage linked to metabolic syndrome.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METABOLIC SYNDROME are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Johns Hopkins Hospital

    Baltimore, Maryland, 21287, United States

Conditions

Explore the condition pages connected to this study.